Search Browse Earnings

Cadrenal Therapeutics, Inc.

Nasdaq:CVKD

Pharmaceutical Preparations·PONTE VEDRA, FL

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Pham Quang X

CFO

Szot Matthew K

Revenue

—

Adj. EBITDA

-$7.6M

FY 2024

Net Income

-$8.4M

FY 2024

EPS (Diluted)

-$9.29

FY 2024

Stock Price

$7.80

-0.8%

2026-03-11

52W Range

$4.91 – $20.39

P/E Ratio

-0.8x

Market Cap

$16.2M

Cash

$10.0M

FY 2024

Total Debt

$597,068

FY 2023

Net Cash

$9.4M

FY 2023

Enterprise Value

$6.8M

Debt / EBITDA

1.2x

FY 2024

EV / EBITDA

-0.9x

Employees

—